Small molecule inhibitors of transcriptional cyclin-dependent kinases impose HIV-1 latency, presenting “block and lock” treatment strategies
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.01072-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Riley M Horvath und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology Molecular Epigenetics Group, LSI, University of British Columbia, Vancouver, British Columbia, Canad…. Hauptthemen laut MEDLINE: HIV-1. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gouvernement du Canada | Canadian Institutes of Health Research (IRSC), Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (NSERC), Michael Smith Health Research BC (MSFHR).
Abstract (Originalsprache)
Current antiretroviral therapy for HIV-1 infection does not represent a cure for infection as viral rebound inevitably occurs following discontinuation of treatment. The “block and lock” therapeutic strategy is intended to enforce proviral latency and durably suppress viremic reemergence in the absence of other intervention. The transcription-associated cyclin-dependent protein kinases (tCDKs) are required for expression from the 5´ HIV-1 long-terminal repeat, but the therapeutic potential of inhibiting these kinases for enforcing HIV-1 latency has not been characterized. Here, we expanded previous observations to directly compare the effect of highly selective small molecule inhibitors of CDK7 (YKL-5-124), CDK9 (LDC000067), and CDK8/19 (Senexin A), and found each of these prevented HIV-1 provirus expression at concentrations that did not cause cell toxicity. Inhibition of CDK7 caused cell cycle arrest, whereas CDK9 and CDK8/19 inhibitors did not, and could be continuously administered to establish proviral latency. Upon discontinuation of drug administration, HIV immediately rebounded in cells that had been treated with the CDK9 inhibitor, while proviral latency persisted for several days in cells that had been treated with CDK8/19 inhibitors. These results identify the mediator kinases CDK8/CDK19 as potential “block and lock” targets for therapeutic suppression of HIV-1 provirus expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology Molecular Epigenetics Group, LSI, University of British Columbia, Vancouver, British Columbia, Canada.
- Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.
- British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
ORCID-Profile: Zabrina L Brumme, Ivan Sadowski
Förderung
- Gouvernement du Canada | Canadian Institutes of Health Research (IRSC)
- Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (NSERC)
- Michael Smith Health Research BC (MSFHR)
Zitieren
APA
Horvath, R. M., Brumme, Z. L., & Sadowski, I. (2024). Small molecule inhibitors of transcriptional cyclin-dependent kinases impose HIV-1 latency, presenting “block and lock” treatment strategies. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01072-23
Vancouver
Horvath RM, Brumme ZL, Sadowski I. Small molecule inhibitors of transcriptional cyclin-dependent kinases impose HIV-1 latency, presenting “block and lock” treatment strategies. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.01072-23
BibTeX
@article{Horvath2024,
author = {Horvath, Riley M and Brumme, Zabrina L and Sadowski, Ivan},
title = {Small molecule inhibitors of transcriptional cyclin-dependent kinases impose HIV-1 latency, presenting “block and lock” treatment strategies},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.01072-23}
}
EUVIMED